Published in Cancer Weekly, December 23rd, 2003
The abstracts were presented at the meeting of the annual AACR-NCI-EORTC International Conference held in Boston 17-21 November 2003. This research supports the conclusion that XR5944 is a novel DNA/RNA targeting agent and that its mechanism of action is distinct from current cytotoxic agents. XR5944 is currently in Phase I clinical development in patients with advanced solid tumors.
Preclinical studies have shown XR5944 to be a highly active and potent cytotoxic agent....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.